title: [Extracorporeal shockwave therapy for erectile dysfunction and Peyronie's disease].
abstract: Penile vascular endothelial damage, vasomotor dysfunction, and blood flow deficiency are the major causes of erectile dysfunction (ED). Current management of ED mostly depends on selective phosphodiesterase type 5- (PDE5) inhibitors, which fail for some ED patients. For Peyronie's disease-induced ED, surgical and physical therapies are used in addition to PDE5I medication, but frequently it is difficult to achieve satisfactory results. Recent studies show that the low-intensity extracorporeal shockwave therapy can promote angiogenesis and improve blood flow to the penis, which promises to be a novel effective therapy for ED and Peyronie's disease.
authors.forename: Ji-Yin
authors.initials: JY
authors.lastname: Zhu
authors.forename: Rui
authors.initials: R
authors.lastname: Jiang
mesh_terms: D007172:Erectile Dysfunction / Q000628:therapy*; D019220:High-Energy Shock Waves / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010411:Penile Induration / Q000628:therapy*